South San Francisco-based Raven biotechnologies has pocketed $48.3 million from its fourth round of venture capital. Vulcan Capital led the round. Raven has been working to develop monoclonal antibody therapeutics for treating cancer.
- read this press release for more
ALSO: Alinea Pharmaceuticals has raised $45 million in its first round of venture capital. MPM Capital Ventures led the round with Flagship Ventures and Burrill & Co. joining in. Alinea is working on a treatment for diabetic neuropathy, a condition involving nerve damage among diabetics. Private Equity Week reports that Alinea is already working on a second round of $25 million. Report
PLUS: Light Sciences Oncology has raised $35 million in its first round. Report
FINALLY: Aerie Pharmaceuticals raised $21 million in its first round. Release
